Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyFidelis Care Actemra/Tyenne Prior Auth Policy | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    DraftFidelis CarePolicy N/A

    Prior Authorization and Coverage Criteria — Actemra (tocilizumab) subcutaneous and Tyenne products

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for Actemra (subcutaneous and ACTPen) and Tyenne (autoinjector and subcutaneous) products for Fidelis Care members in North Carolina; it affects prescribers, pharmacists, and prior authorization reviewers.

    Policy Summary
    PayerFidelis Care
    PolicyActemra (tocilizumab) subcutaneous and Tyenne coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required documentation including diagnosis, prior therapies, and any required lab or mutation test results.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+distinct products listed in this excerpt
    1 yrcoverage duration (typical)
    ≥18age restriction ILD
    requirementsstep/biologic trial requirements
    NCapplicable state

    Coverage Criteria by Product / Indication

    inv-01: Initial and Continuation Therapy Criteria

    Covered when ALL of the following are met for the specified indication groups:

    Rheumatoid Arthritis (Initial)

    • A - Step therapy: Patient tried two of the following: Enbrel; preferred adalimumab product; Rinvoq or Xeljanz/XR. Trials with Cimzia, infliximab, golimumab SC/IV, or non-preferred adalimumab also count toward the two-agent requirement.
    • B - Alternative condition: Patient has heart failure OR a previously treated lymphoproliferative disorder.

    Polyarticular Juvenile Idiopathic Arthritis (Initial)

    • A - Step therapy: Patient tried two of the following: Enbrel; Rinvoq; Xeljanz; preferred adalimumab product. Trials with infliximab or a non-preferred adalimumab product also count.
    Policy Summary
    PayerFidelis Care
    PolicyActemra (tocilizumab) subcutaneous and Tyenne coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and submit required documentation including diagnosis, prior therapies, and any required lab or mutation test results.
    SourceLink
    On This Page
    Coverage Criteria by Product / IndicationCode Tables and Key ValuesPrior Authorization, Documentation, and Step TherapyTerms and Diagnostic DefinitionsBackground and ScopePolicy Revision History
  1. B - Alternative condition: Patient has heart failure or a previously treated lymphoproliferative disorder.
  2. Giant Cell Arteritis (Initial): Patient tried or is currently taking a systemic corticosteroid OR systemic corticosteroid is contraindicated.

    Interstitial Lung Disease associated with Systemic Sclerosis (Initial)

    • A - Lab: Elevated acute phase reactants.
    • B - Imaging: Diagnosis confirmed by high-resolution computed tomography (HRCT).
    Continuation Therapy (All Indications): Patient had a response to therapy.

    inv-02: Benlysta (belimumab) — SLE and Lupus Nephritis

    Covered when the specified diagnosis-specific and concurrent therapy criteria are met.

    Benlysta for SLE - Initial: Patient has autoantibody-positive SLE (positive ANA and/or anti-dsDNA) AND Benlysta is used concurrently with at least one other standard therapy (antimalarials, systemic corticosteroid, and/or other immunosuppressants) unless intolerant to those therapies AND prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist, or dermatologist AND patient is >=5 years of age for initial therapyage >= 5 years

    Initial coverage duration 4 months

    Benlysta for SLE - Continuation: Benlysta is being used concurrently with at least one other standard therapy unless intolerant AND patient has responded to Benlysta subcutaneous or intravenous AND prescriber specialty as aboveresponse to therapy

    Continuation coverage duration 1 year

    Benlysta for Lupus Nephritis - Initial: Patient has a diagnosis of lupus nephritis AND Benlysta is being used concurrently with an immunosuppressive regimen (e.g., azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid) AND prescribed by a nephrologist or rheumatologistconcurrent immunosuppressive regimen

    Initial coverage duration 6 months

    Benlysta for Lupus Nephritis - Continuation: Benlysta is used concurrently with an immunosuppressive regimen AND the patient has responded to Benlysta subcutaneous or intravenousresponse to therapy

    Continuation coverage duration 1 year

    inv-03: Cosentyx (secukinumab) — Psoriasis, Psoriatic Arthritis, AS, HS, others

    Covered when indication-specific prior treatment and prescriber criteria are satisfied.

    Plaque Psoriasis (PP) Initial Options: Either (A) patient tried at least one traditional systemic agent (e.g., methotrexate, cyclosporine, acitretin, PUVA) for >=3 months unless intolerant (a trial of at least one biologic that is not Cosentyx counts), OR (B) contraindication to methotrexate>=3 months trial of traditional systemic agent

    Initial approvals for PP require prior trial or contraindication

    General Cosentyx Prescribing and Age Restrictions: Diagnosis and previous medication use documented; age limits vary by indication (e.g., PP >=6 years; PsA >=2 years; AS initial >=18 years; Enthesitis >=4 years; HS initial >=18 years) AND initial prescriber restrictions by indication (e.g., PP initial by or in consultation with dermatologist; PsA initial by or in consultation with dermatologist or rheumatologist; AS by rheumatologist; HS by dermatologist)age per indication

    Continuation: patient has experienced benefit from medication; coverage through end of plan year

    Hidradenitis Suppurativa (HS) Initial: Patient tried at least one other therapy (e.g., systemic antibiotics, isotretinoin) AND initial prescriber is or consulted with dermatologistprior therapy trial

    Initial HS requires prior non-biologic therapy

    Non-radiographic axial spondyloarthritis (non-radiographic axial) Initial: Evidence of elevated inflammatory markers (e.g., CRP) beyond upper limit of normal OR sacroiliitis on MRIelevated CRP or sacroiliitis on MRI

    Supports diagnosis for coverage

    inv-04: Ambrisentan/Bosentan — Pulmonary Arterial Hypertension (PAH)

    Covered for WHO Group 1 PAH with diagnostic confirmation.

    PAH Coverage: Diagnosis of pulmonary arterial hypertension (WHO Group 1) with results of right-heart catheterization to confirm diagnosis AND prescribed by or in consultation with a cardiologist or pulmonologistright-heart catheterization documented

    Authorization for one year

    CTEPH (bosentan): For chronic thromboembolic pulmonary hypertension (CTEPH), patient must have tried Adempas, have contraindication to Adempas, or is currently receiving bosentan for CTEPHtrial or contraindication to Adempas

    Off-label/medically-accepted indication noted for bosentan

    inv-05: Haegarda (C1-INH) — Hereditary Angioedema (HAE)

    Covered when diagnostic criteria and response criteria are met.

    HAE Type I/II Continuation: Diagnosis of HAE type I or II confirmed by low functional C1-INH (<50% normal) and low C4 at baseline AND patient is currently taking Haegarda for prophylaxis AND prescriber documents favorable clinical response since initiationC1-INH <50% and low C4; clinical response documented

    Authorization for one year

    HAE with normal C1-INH: Either (1) patient tested positive for an F12, ANGPT1, PLG, KNG1, HS3ST6, or MYOF gene mutation OR (2) patient has family history of angioedema and angioedema refractory to high-dose antihistamine therapy for >=1 monthgenetic test positive OR refractory to antihistamines

    Covers HAE with normal C1-INH under specified criteria

    inv-06: Dupixent — Initial and continuation therapy criteria

    Covered with criteria when ALL specified indication-specific criteria are met

    Dupixent - COPD initial: All of: A) blood eosinophil >=300 cells/µL within previous 6 weeks; B) received >=3 months combination therapy with at least two of LAMA, LABA, or ICS; C) either two or more COPD exacerbations in previous 12 months requiring systemic CS or antibiotics OR COPD exacerbation requiring hospitalization in previous 12 months.as stated

    chunk 47

    Dupixent - CSU initial: Urticaria >6 weeks with symptoms >=3 days/week despite daily non-sedating H1 antihistamine therapy.as stated

    chunk 47

    Dupixent - Atopic Dermatitis initial: Tried at least 1 medium to super-high-potency topical corticosteroid unless not advisable or patient <2 years.as stated

    chunk 49

    Dupixent - Asthma initial: All of: A) blood eosinophil >=150 cells/µL within previous 6 weeks or oral CS-dependent asthma; B) used an ICS plus at least one additional controller; C) uncontrolled asthma defined by one of: two or more exacerbations needing oral CS in past year; one or more exacerbation requiring hospital/urgent care/ED in past year; FEV1 <80% predicted (adults); FEV1/FVC <0.8; or worsened asthma with oral CS taper.as stated

    chunk 49

    Dupixent - CRSwNP initial: All of: A) concurrent nasal corticosteroid use; B) at least two symptoms for 6 months (nasal congestion/obstruction, nasal discharge, loss of smell); C) received oral CS >=5 days in last 2 years or prior nasal polyp surgery; D) diagnosis confirmed by direct exam, endoscopy, or sinus CT.as stated

    chunk 50

    Dupixent - EoE initial: All of: A) weight >=15 kg; B) endoscopic biopsy >=15 intraepithelial eosinophils per HPF; C) no secondary cause of EoE; D) received Rx-strength PPI for >=8 weeks.as stated

    chunk 50

    Dupixent - Continuation: Indication-specific demonstration of benefit after specified duration (e.g., >=6 months for many indications; AD continuation requires positive response), and continued concurrent therapies where required.as stated

    chunk 50

    inv-07: Enbrel — Initial and continuation therapy criteria

    Covered when ALL of the applicable indication-specific criteria are met

    Enbrel - RA initial: Tried one conventional synthetic DMARD for >=3 months (see Note 1).as stated

    chunk 53

    Enbrel - JIA/JRA initial: One of: aggressive disease; tried one other systemic therapy; will be started concurrently with MTX/sulfasalazine/leflunomide; or absolute contraindication to those agents.as stated

    chunk 53

    Enbrel - Plaque Psoriasis initial: Either tried >=1 traditional systemic agent for >=3 months unless intolerant OR contraindication to MTX/other oral agent.as stated

    chunk 53

    Enbrel - Continuation: Patient had a response to therapy (all indications).as stated

    chunk 54

    inv-08: Doptelet — Indication-specific criteria

    Covered when ALL of the following indication-specific criteria are met

    Doptelet - Thrombocytopenia with chronic liver disease: A) current platelet count <50 x 10^9/L; B) scheduled to undergo a procedure within 10-13 days after starting therapy.as stated

    chunk 45

    Doptelet - Chronic ITP initial: A) platelet count <30,000/µL OR platelet count <50,000/µL with increased bleeding risk; B) tried one other therapy (eg systemic corticosteroids, IVIG, anti-D, eltrombopag, romiplostim, fostamatinib, rituximab) or had splenectomy.as stated

    chunk 45

    Doptelet - Chronic ITP continuation: Patient had beneficial clinical response and remains at risk for bleeding complications.as stated

    chunk 45

    inv-09: Cystagon — Diagnostic confirmation requirement

    Covered when ALL criteria are met

    Cystagon - Cystinosis, nephropathic initial: Diagnosis confirmed by genetic testing showing CTNS mutation OR WBC cystine concentration above lab reference range.as stated

    chunk 40

    inv-10: Cresemba — Indication-specific criteria

    Covered when ALL applicable criteria are met

    Cresemba - Melanoma combination: Melanoma (unresectable/advanced/metastatic) when prescribed in combination with Zelboraf and patient is BRAF V600 mutation positive.as stated

    chunk 38

    Cresemba - CNS/neoplasm uses: Approve for specific CNS tumor adjuvant settings, recurrent/progressive disease, or melanoma with brain metastases when used with Zelboraf per listed situations.as stated

    chunk 38

    Cresemba - Histiocytic neoplasm: Approve for Langerhans cell histiocytosis with multisystem/pulmonary/CNS lesions, Erdheim-Chester disease, or Rosai-Dorfman disease per criteria.as stated

    chunk 38

    inv-11: Dalfampridine — Ambulation and response criteria

    Covered when ALL criteria are met

    Dalfampridine - Initial: Patient is ambulatory, medication used to improve/maintain mobility in MS, and patient has impaired ambulation as evaluated by objective measure (eg timed 25-foot walk, MSWS-12).as stated

    chunk 40

    Dalfampridine - Continuation: Patient is ambulatory, medication used to improve/maintain mobility in MS, and patient has responded to or is benefiting from therapy.as stated

    chunk 40

    inv-12: Deferasirox — Ferritin-based initiation and continuation

    Covered when ALL criteria are met

    Deferasirox - Transfusion-related chronic iron overload initial: Patient receiving regular blood transfusions AND serum ferritin >1000 mcg/L prior to starting therapy.>1000 mcg/L

    chunk 42

    Deferasirox - Non-transfusion-dependent thalassemia initial: Serum ferritin >300 mcg/L prior to starting therapy.>300 mcg/L

    chunk 42

    Deferasirox - Continuation: Patient is benefiting from therapy as confirmed by prescribing physician.as stated

    chunk 42

    inv-13: Diacomit & Epidiolex — Seizure disorder criteria

    Covered when ALL criteria are met

    Diacomit - Dravet syndrome initial: Patient >=6 months and is concomitantly receiving clobazam or is unable to take clobazam due to adverse events; prescribed by or in consultation with a neurologist.as stated

    chunk 43

    Epidiolex - Dravet/Lennox/TSC initial: Patient meets age criteria and has tried or is concomitantly receiving at least two other antiseizure drugs (with specified exceptions for Diacomit/clobazam/Fintepla for Dravet); prescribed by or in consultation with a neurologist.as stated

    chunk 55

    Epidiolex - Continuation: Patient is responding to therapy.as stated

    chunk 55

    inv-14: Elrexfio — Prior regimen requirement

    Covered when ALL criteria are met

    Elrexfio - Multiple myeloma: Patient has tried at least four systemic regimens and among prior regimens received at least one drug from each class: proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody (per FDA labeling).as stated

    chunk 51

    inv-15: Cosentyx — Initial therapy requirements

    Covered when ALL criteria are met

    Cosentyx - Plaque psoriasis and other indications: Initial therapy requires trial of at least one traditional systemic agent for PP (or contraindication) or prior biologic (not Cosentyx) may count; age restrictions vary by indication (pediatric down to 4 or 6 years depending on condition).as stated

    chunk 37

    Cosentyx - HS initial: Tried at least one other therapy (eg systemic antibiotics, isotretinoin).as stated

    chunk 37

    inv-16: Initial Therapy — Fasenra (Asthma)

    Fasenra — Initial therapy for asthma

    Fasenra initial asthma criteria: A) blood eosinophil >=150 cells/µL within previous 6 weeks or within 6 weeks prior to Fasenra or another monoclonal antibody; B) used an inhaled corticosteroid (ICS) with at least one additional asthma controller/maintenance medication; C) uncontrolled asthma prior to any asthma monoclonal antibody as defined by one of: a) >=1 exacerbation requiring systemic corticosteroid in past year; b) >=1 exacerbation requiring hospital/urgent care/ED visit in past year; c) FEV1 <80% predicted (or <90% if <18 years); d) FEV1/FVC <0.80; e) worsened asthma with systemic corticosteroid taper.see text

    All A, B, and C required

    inv-17: Continuation Therapy — Fasenra

    Fasenra — Continuation therapy

    Fasenra continuation criteria: A) patient has responded to therapy (e.g., decreased exacerbations, symptoms, hospitalizations, ED visits, physician visits, or oral corticosteroid requirement) AND B) continues to receive therapy with an ICS.response documented

    Both A and B required

    inv-18: Initial Therapy — Exkivity

    Exkivity (mobocertinib) criteria

    ref':'b0_18
    title':'inv-18: Initial Therapy — Exkivity'
    note_json_error_fixing_removed_here

    Code Tables and Key Values

    Listed productsmixed
    drug listMultiple product names and formulations (e.g., Cosentyx, Cotellic, Cresemba, Cystaran, Cystagon, dalfampridine, Daurismo, deferasirox, dihydroergotamine nasal, Diacomit, dimethyl fumarate, Doptelet, droxidopa, Dupixent, Elrexfio, Emgality, Enbrel, Epidiolex)
    Products referencedmixed
    Product listMultiple products enumerated (e.g., Eligard, gabapentin ER, Omnitrope, Ibrance, Imbruvica, icatibant, Iclusig, Idhifa, imatinib, Ingrezza, Inlyta, Inrebic, etc.)
    Drugs Listed (no codes provided)mixed
    N/AMultiple drug-specific entries; no explicit CPT/HCPCS/ICD codes listed in this segment
    Prior authorization affected codes (placeholder)mixed
    affected codesplaceholder — document references PA applicability to specific codes (see full policy)
    No explicit CPT/HCPCS/ICD codes in this segmentmixed
    No codes listed
    No codes provided in this partmixed
    N/ANo explicit CPT/HCPCS/ICD codes listed in this section
    No explicit CPT/HCPCS/ICD-10 codes provided in this partmixed
    No codes listed
    No explicit CPT/HCPCS/ICD-10 codes provided in this sectionmixed
    No codes listed
    Coverage duration
    Authorization periodApprove through end of plan year
    Typical alternative duration noted elsewhereMany products: 12 months or 1 year (when specified)
    Initial-specific exceptionsSome initial approvals (e.g., Benlysta SLE 4 months; Benlysta lupus nephritis 6 months; Livtencity 2 months)
    Age restriction for ILD
    Age restriction (ILD)18 years and older — applies to initial and continuation therapy
    Prescriber requirement (ILD)Prescribed by or in consultation with a pulmonologist (or rheumatologist for systemic sclerosis-associated ILD)
    Related coverage noteFVC thresholds also apply (see FVC threshold block) for IPF and systemic sclerosis ILD
    Eosinophil or diagnostic thresholds
    Asthma (Fasenra/Dupixent)Blood eosinophil ≥150 cells/µL (Fasenra) or ≥150–300 cells/µL as specified for Dupixent/COPD indications
    COPD (Dupixent)Blood eosinophil ≥300 cells/µL within prior 6 weeks for Dupixent COPD initial
    EoE (Dupixent) diagnosticEndoscopic biopsy ≥15 intraepithelial eosinophils per high-power field
    General noteEosinophil thresholds are time‑bound (within prior 4–6 weeks) per product-specific criteria
    Fasenra blood eosinophil count
    Fasenra blood eosinophil requirement>= 150 cells per microliter (documented within previous 6 weeks)
    Associated requirementsPlus use of ICS with at least one additional controller and evidence of uncontrolled asthma prior to biologic
    ContinuationResponse to therapy documented for continuation authorization
    Hemoglobin thresholds for ESA therapy (Retacrit)
    Initial ESA (CKD not on dialysis) thresholdHemoglobin < 10.0 g/dL for adults (initial)
    Continuation ESA thresholdHemoglobin <= 12.0 g/dL for patients currently on an ESA
    MDS-specific thresholdInitial Hb < 10 g/dL or serum erythropoietin <= 500 mU/mL
    GH stimulation test peak thresholds
    GH stimulation test peak cutoffs (examples)Failed: peak GH <10 ng/mL; ITT peak GH ≤5 ng/mL; Macrilen peak <2.8 ng/mL; GST peak ≤3 ng/mL depending on BMI and test
    Test-dependent variabilitySpecific peak thresholds vary by stimulation test type and patient BMI/pretest probability
    Pediatric requirementPediatric diagnosis may require two failed stimulation tests per criteria
    IGF-1 and height thresholds
    IGF‑1 threshold (GHD)IGF‑1 >2 standard deviations below the mean for age/gender (low IGF‑1) — used to support GHD diagnosis
    Height thresholdHeight >2 SD below mean or reduced growth velocity per age-specific criteria for pediatric GHD
    SGA criteriaSmall for gestational age defined by birth weight <2500 g at GA >37 weeks or birth weight/length <3rd percentile
    Baseline IGF-1 — above upper limit of normal
    Baseline IGF‑1 requirement (acromegaly)Baseline IGF‑1 level above the laboratory upper limit of normal for age and gender (documented prior to approval)
    PurposeUsed to confirm active disease and support need for somatostatin analog therapy or other acromegaly treatments
    PrescriberPrescribed by or in consultation with an endocrinologist for acromegaly indications
    Livtencity weight threshold
    Livtencity minimum weight>= 35 kg (patient must weigh at least 35 kilograms)
    ContextApplies to post‑transplant CMV refractory/intolerant treatment eligibility
    DocumentationPatient must be post-transplant and CMV refractory to or intolerant of listed antivirals
    Migraine days/month — preventive therapy
    Preventive episodic migraine days/month>= 4 and < 15 migraine headache days per month prior to initiating preventive therapy
    Continuation requirementPatient must demonstrate significant clinical benefit for continuation
    Concurrent CGRP exclusionConcurrent use with another CGRP inhibitor for prevention is an exclusion when using Nurtec ODT for prevention
    Febrile neutropenia risk threshold
    Febrile neutropenia (FN) chemotherapy risk threshold>= 20% regimen-associated risk of FN — CSF prophylaxis indicated for high-risk regimens
    Lower-risk regimensIf regimen FN risk <20% then patient-specific risk factors (eg age >=65, prior chemo/radiation, marrow involvement) may justify CSF use
    DocumentationChemotherapy regimen and FN risk must be documented for PA decision-making
    FVC threshold for IPF/ILD
    FVC thresholds (IPF/Systemic SSc ILD)FVC >= 40% predicted required for IPF and systemic sclerosis ILD initial therapy
    Chronic fibrosing ILD initialFVC >= 45% predicted plus >10% fibrosing lung involvement on HRCT and clinical progression required
    Diagnostic requirementDiagnosis must be confirmed by HRCT (UIP pattern) or surgical lung biopsy where specified
    LDL-C thresholds
    Untreated LDL‑C thresholdsExamples: untreated LDL‑C >= 190 mg/dL (HeFH) or untreated LDL‑C > = 400 mg/dL for HoFH
    Post‑statin treated thresholdsTreated LDL‑C goals differ by phenotype (eg LDL‑C remains >=70 mg/dL for HeFH post‑statin; >=55 mg/dL for established CVD per criteria)
    Phenotype-specific documentationPhenotypic confirmation, Dutch Lipid Network score or Simon Broome criteria may be required for HeFH/HoFH
    Desmoid tumor progression — progression threshold
    Desmoid tumor progression requirement>= 20% tumor progression within 12 months (defines 'progressing' desmoid tumors)
    Treatment contextApplies when tumors are not amenable to surgery or radiotherapy and systemic therapy is required
    AuthorizationCoverage typically authorized for 1 year when criteria met
    LDL-C thresholds for lipid disorders
    HeFH untreated LDL-CUntreated LDL‑C >=190 mg/dL (>=155 mg/dL if <16 years) or phenotypic confirmation
    HoFH thresholdsUntreated LDL‑C >400 mg/dL or treated LDL‑C >=300 mg/dL with early clinical manifestations; phenotypic confirmation required
    Established CVD treated thresholdLDL‑C remains >=55 mg/dL after high‑intensity statin or patient is statin‑intolerant
    ALSFRS-R score requirement
    ALSFRS‑R score requirementScore of two points or more on each item of the ALSFRS‑R required for initial Radicava ORS approval
    Diagnostic criteriaDefinite or probable ALS per El Escorial or revised Airlie House criteria also required
    PrescriberPrescribed by or in consultation with neurology/ALS specialist; respiratory function adequate
    Baseline IgE — >= 30 IU/mL
    Baseline IgE requirement (Xolair)>= 30 IU/mL (baseline, prior to Xolair or other monoclonal antibody that may lower IgE)
    Associated testingPositive skin prick or in vitro test for relevant aeroallergens typically required for asthma/CRwNP/food allergy indications
    Indication-specific age limitsAge limits vary by indication (eg asthma >=6 years; CIU >=12 years; food allergy >=1 year)
    Recurrent pouchitis episodes
    Recurrent pouchitis episodes>= 3 episodes within 12 months (typically defines 'recurrent pouchitis')
    Antibiotic response/relapse requirementEpisodes must respond to antibiotics but relapse after discontinuation
    Prior antibiotic trialsTried long‑term ciprofloxacin and metronidazole (≥4 weeks each) for remission maintenance prior to Xifaxan approval
    PSA doubling time (Xtandi) — threshold
    PSA doubling time (high‑risk biochemical recurrence)<= 9 months — qualifies as high‑risk biochemical recurrence for Xtandi coverage in non‑metastatic castration‑sensitive disease
    Concurrent therapy requirementXtandi must be used with a GnRH analog or patient must have had bilateral orchiectomy when required
    Authorization durationTypically authorized for 1 year when criteria met

    Prior Authorization, Documentation, and Step Therapy

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for many specialty, oncology, and high-risk medications. Approvals are typically granted through the end of the plan year or for specified durations in the criteria. Document the diagnosis, prior therapies/trials, relevant laboratory or genetic test results, prescriber specialty or consultation, and any required procedure evidence (e.g., right-heart catheterization for PAH). Denials may occur for concurrent biologic/tsDMARD use, missing diagnostic confirmation, disallowed drug combinations, drug-drug interactions, or failure to meet age/prescriber restrictions.

    • Always include diagnosis, concurrent medications, prior drugs tried and length of trials.
    • Document specialist consultation or that medication is prescribed by an appropriate specialist when required.
    • If criteria are met, authorization durations are commonly 6–12 months or through the plan year as specified.
    Billing Rule

    Part B vs Part D PA Determination

    Part B vs Part D determinations for physician-administered or infusion/clinic-dispensed products (and some oral oncology agents) will be made at time of prior authorization review per CMS guidance. Indicate site of care, route of administration, and clinical rationale on the PA request to allow correct benefit routing.

    • Examples in the formulary note that Part B/Part D determination will be made at PA review (e.g., Elrexfio, Firmagon, Talvey, Ruxience).
    • Include documentation of infusion/administration setting when relevant.
    Documentation Required

    Itraconazole — Indication-Specific Durations and Diagnostic Confirmation

    Itraconazole oral systemic therapy durations differ by indication — ensure the correct duration is requested and documented.

    • Systemic fungal infections: approval up to 12 months.
    • Onychomycosis: fingernail therapy typically 2 months; toenail therapy typically 3 months.
    • Confirm fungal diagnostic test (KOH, culture, or nail biopsy) for onychomycosis.
    Prior Authorization

    Long-Acting Opioids — PA and Documentation Requirements

    Long-acting opioid agents require prior authorization for chronic, around-the-clock pain only. Acute pain and opioid-naive patients are excluded.

    • Approval requires: evidence pain is chronic and severe enough to require daily, long-term opioid therapy; patient is not opioid naïve; non-opioid therapies have been tried and are being used in conjunction; PDMP check; prescriber discussed risks/benefits; and an opioid treatment plan with reassessment schedule is documented.
    • Typical authorization duration: 12 months. Exemptions: cancer, hospice, sickle cell disease, long-term care residents.
    Prior Authorization

    PA for Colony Stimulating Factors (CSFs) — Tied to Febrile Neutropenia Risk

    Colony-stimulating factors (CSFs) used for prophylaxis are authorized when the chemotherapy regimen confers a high risk of febrile neutropenia (≥20%) or when intermediate risk (<20%) with patient-specific risk factors; document chemo regimen and FN risk.

    • Approve for patients receiving myelosuppressive anti-cancer meds associated with ≥20% FN risk, or for <20% risk with one or more physician-documented risk factors (eg, age ≥65, prior chemo/radiation, persistent neutropenia, bone marrow involvement, poor performance status, HIV).
    • Document indication (prophylaxis vs treatment), chemotherapy regimen, and prescriber specialty (oncologist/hematologist).
    Documentation Required

    Ofev — Diagnostic Confirmation and FVC Documentation Required

    Ofev (nintedanib) and other antifibrotic/ILD agents require diagnostic confirmation and lung function thresholds for approval. Prescriber specialty and imaging/lab documentation must be provided.

    • For IPF and ILD‑SSc: diagnosis confirmed by HRCT or biopsy as specified; FVC threshold commonly ≥40% predicted for initial approval (confirm per product criteria).
    • Prescribed by or in consultation with a pulmonologist; include HRCT report and pulmonary function test (PFT) results in the PA.
    Prior Authorization

    Turalio — Prior Authorization Requirement

    Turalio (pexidartinib) requires PA with documentation that the tumor is not amenable to surgery and prescriber documentation of diagnosis.

    • Indication: Tenosynovial giant cell tumor (pigmented villonodular synovitis) — approve if tumor is not amenable to surgery per prescriber.
    • Prescriber specialty documentation and treatment rationale should be included.
    Prior Authorization

    Budesonide (oral) — Prior Authorization and Prior Therapy Requirement

    Oral budesonide delayed-/extended-release requires trial and failure/intolerance of an aminosalicylate for inflammatory bowel disease indications before approval; document prior trial.

    • PA requires documentation of inadequate response or intolerance to a 4‑week trial of an aminosalicylate (eg, sulfasalazine, mesalamine).
    • Coverage duration: 2 months initial.
    Denial Risk

    Concurrent Biologic or tsDMARD Use — Exclusion/Denial Risk

    Concurrent use of biologic or targeted synthetic DMARDs (tsDMARDs) is routinely excluded and will trigger denial unless the policy explicitly allows combination therapy. Document any exceptions or rationale.

    • Many biologic agents list 'Concurrent use with other biologic or targeted synthetic DMARD' as an exclusion (e.g., multiple anti-TNF, anti-IL products, or JAK inhibitors).
    • If prior or concomitant biologic/tsDMARD use is clinically necessary, provide robust justification and specialist consultation notes.
    Documentation Required

    Right‑Heart Catheterization Required for PAH Agents

    Pulmonary arterial hypertension (PAH) therapies require hemodynamic confirmation via right‑heart catheterization (RHC). Include the RHC report with PA requests.

    • PAH (WHO Group 1) must be confirmed by right‑heart catheterization to support initiation of PAH‑specific agents.
    • Prescriber should be a cardiologist or pulmonologist or include consultation documentation.
    Denial Risk

    Drug Interaction Denial Risk — Potent CYP3A4 and Other Contraindications

    Some agents are denied when used with known interacting drugs. Check for potent CYP3A4 inhibitors and other contraindicated combinations and document medication reconciliation.

    • Coverage will be denied for products with explicit interaction exclusions (eg, drugs contraindicated with potent CYP3A4 inhibitors such as ritonavir, nelfinavir, indinavir, clarithromycin, erythromycin).
    • Provide a current medication list and, if interaction exists, an explanation why the concomitant medication cannot be changed.
    Billing Rule

    Medicare Part D / ESRD Coverage — Denial Risk

    Medicare Part D coverage exclusions apply for certain ESRD-related or dialysis-administered anemia products — verify benefit and document dialysis status.

    • Some anemia/ESRD products have Medicare Part D/ESRD coverage restrictions; document dialysis status and indication.
    • If product is excluded under Part D for dialysis patients, indicate in PA to avoid inappropriate approvals.
    Documentation Required

    Geriatric HRM Acknowledgement and Prior Trials for Age ≥65

    Geriatric high‑risk medication (HRM) prior authorization rules require prescriber acknowledgment and, in many cases, documentation of prior trials in patients 65+. Ensure the prescriber documents risk/benefit and prior alternatives tried.

    • Many HRMs require prescriber acknowledgement that benefits outweigh risks for patients 65 years or older and documentation of inadequate response/intolerance to safer alternatives.
    • Examples include anticholinergics, benzodiazepines, and select sedative/hypnotics.
    Prior Authorization

    Sofosbuvir‑Velpatasvir — Guidance‑Aligned Criteria and Combination Exclusion

    Sofosbuvir‑velpatasvir (DAA) PA requires adherence to AASLD/IDSA guidance and excludes combination use with other direct‑acting antivirals; document genotype, prior HCV treatment history, and prescriber specialty.

    • Exclude combination use with other DAAs (ribavirin is an exception where clinically indicated).
    • PA applied consistent with current AASLD/IDSA guidance; include HCV genotype, prior therapies, and liver disease staging.
    Documentation Required

    Opioid Therapy — Required Documentation

    Opioid therapy approvals require thorough documentation of indications, prior pain therapies, PDMP checks, treatment planning, and risk mitigation counseling.

    • Document pain type (chronic vs acute), prior pain medications/therapies tried, concurrent medications, PDMP review, risk/benefit discussion, and a written treatment plan with reassessment intervals.
    • Exclude acute (non‑chronic) pain from long‑acting opioid approvals.
    Documentation Required

    Genetic / Laboratory Documentation — Required for Many Specialty Agents

    Genetic and laboratory test documentation is required for many enzyme-replacement, targeted oncology, and genetic disorder therapies — include specific test names, results, and dates.

    • Examples: EGFR, PIK3CA, BRAF, FLT3, BRCA, GLA activity (Fabrazyme), alpha‑glucosidase (Lumizyme), TTR sequencing (Vyndaqel/Vyndamax), and sucrase‑isomaltase testing for Sucraid.
    • Attach approved test reports and reference ranges; note test method and specimen source where relevant.
    Documentation Required

    Growth Hormone — Diagnostic Testing and Baseline IGF‑1 Required

    Growth hormone therapies require specific diagnostic testing and IGF‑1 documentation prior to approval; include stimulation test results or baseline IGF‑1 per indication.

    • Pediatric GHD: growth metrics, failed stimulation tests (two tests), or algorithm-specified criteria; include pre‑treatment IGF‑1 as required.
    • Adult GHD: failed two stimulation tests or IGF‑1 >2 SD below mean with supporting pituitary disease documentation.
    Documentation Required

    Onychomycosis — Diagnostic Confirmation Required for Systemic Therapy

    Onychomycosis (toenail/fingernail) systemic therapy requires fungal diagnostic confirmation before approving oral antifungals like itraconazole.

    • Acceptable diagnostics: KOH prep, fungal culture, or nail biopsy demonstrating dermatophyte infection.
    • Document prior topical therapies and reasons for systemic therapy if requested.
    Documentation Required

    Baseline IGF‑1 and Endocrinology Documentation (Acromegaly)

    Acromegaly therapies and other endocrine agents commonly require baseline IGF‑1 documentation and endocrinology consultation; include lab reference ranges and date of testing.

    • Acromegaly initial approval requires a baseline IGF‑1 above the upper limit of normal for age and sex and documentation of prior surgery/radiotherapy attempts or contraindication.
    • Attach lab reports with reference ranges and date.
    Documentation Required

    Lapatinib — Diagnostic and Prior Therapy Documentation Required

    Lapatinib and other targeted oncology agents require documentation of tumor biomarker status and prior therapy regimens (eg, HER2 status, prior anti‑HER2 regimens).

    • Lapatinib: for HER2‑positive metastatic breast cancer, document HER2 status and that patient has tried at least two anti‑HER2 based regimens when used in combination with capecitabine or trastuzumab as specified.
    • Include pathology/biomarker reports and prior oncology treatment history with dates.
    Documentation Required

    Lumizyme — Diagnostic Testing Required

    Lumizyme and similar enzyme‑replacement therapies require confirmatory enzymatic or genetic testing prior to approval.

    • Provide laboratory demonstration of deficient enzyme activity (eg, acid alpha‑glucosidase) in blood, fibroblasts, or muscle tissue or a pathogenic molecular genetic test.
    • Prescriber should be a relevant specialist (geneticist, metabolic disease specialist).
    Documentation Required

    Livtencity — Clinical and Weight Documentation Required

    Livtencity (and weight‑sensitive agents) approvals require clinical measures including weight and indication‑specific documentation.

    • Document patient weight and clinical indications per product labeling; include any prior therapies required for the indication (eg, lifestyle interventions).
    • Prescriber specialty and rationale for agent selection should be included.
    Documentation Required

    ALS — ALSFRS‑R and Neurology Consultation Documentation

    ALS‑specific therapies require ALSFRS‑R scores and neurology/ALS specialist documentation to support initiation and continuation.

    • Provide ALSFRS‑R score components and overall function demonstrating retained activities of daily living as specified (eg, score of 2 or more on each item when required).
    • Include neurologist or neuromuscular disease specialist consultation notes and respiratory function documentation.
    Step Therapy

    Step Therapy / Prior Biologic Trials — Documentation Required

    Step therapy and prior biologic trials are commonly required for immunology and rheumatology agents; document trials and durations of prior therapies.

    • Policies frequently require trials of conventional systemic agents (eg, methotrexate for RA or plaque psoriasis) or trials of specified biologics/non‑preferred agents prior to approving newer agents.
    • Examples: Cosentyx and other biologics often require trial of at least one traditional systemic agent or biologic depending on indication; RA agents may require trials of two TNFi or specified DMARDs.
    Documentation Required

    ILD‑SSc and ILD — HRCT, Lab, and Prescriber Requirements

    Interstitial lung disease associated with systemic sclerosis (ILD‑SSc) and other ILD indications require diagnostic confirmation (HRCT), elevated acute‑phase reactants where specified, and PFT documentation.

    • Provide HRCT report confirming diagnosis and include FVC and other PFT values; some policies require elevated acute phase reactants as part of initial criteria.
    • Prescriber should be pulmonologist or rheumatologist as specified.
    Step Therapy

    Oncology Step Therapy and Prior Treatment Documentation

    Oncology step requirements and prior therapies must be documented per regimen-specific criteria (eg, Jakafi, Mekinist/Tafinlar combinations, lapatinib combinations).

    • Document mutation status (EGFR, BRAF V600, FLT3, BRCA, PIK3CA, etc.) and prior lines of systemic therapy with agents and dates.
    • Example: Jakafi prior therapy/step requirements must be documented where specified; Mekinist/Tafinlar approvals require BRAF V600 mutation documentation and combination partner confirmation.
    Step Therapy

    Jakafi — Step Therapy / Prior Treatments Documentation

    Specific step therapy prior treatments for Jakafi (ruxolitinib) and similar agents must be documented when required by the policy.

    • For GVHD or myelofibrosis indications where step rules apply, include prior conventional systemic treatments tried (eg, corticosteroids, other agents) and response/intolerance documentation.
    • Attach prior treatment dates and prescriber specialty notes.

    Terms and Diagnostic Definitions

    Continuation therapy response
    Response required for continuationPatient must have had a response to therapy — documented clinical benefit is required for continuation authorization
    Applies toContinuation therapy requirement applies across indications (specified per-product continuation rules)
    DocumentationPrescriber must document clinical benefit since initiation for continuation approvals
    Autoantibody-positive SLE definition
    Autoantibody-positive SLE definitionPositive for antinuclear antibodies (ANA) and/or anti-double‑stranded DNA (anti‑dsDNA) antibody
    Context of useRequired for Benlysta initial SLE coverage alongside concurrent standard therapy documentation
    Age noteBenlysta initial therapy age threshold: >=5 years (as specified) — separate from autoantibody definition
    HAE type I/II diagnostic criteria
    HAE type I/II diagnostic criteriaLow functional C1‑INH protein (<50% of normal) at baseline AND low serum C4 levels at baseline (per laboratory reference)
    PrescriberPrescribed by or in consultation with an allergist/immunologist or HAE specialist for initial/continuation
    Continuation evidenceFor prophylaxis continuation, prescriber must document favorable clinical response since initiating therapy
    Continuation therapy — definition and expectations
    Continuation therapy definitionOngoing authorization contingent on documented clinical benefit or response to therapy after initial approval period
    Timing examplesMany products require demonstration of benefit after specified initial months (eg 4 months for Benlysta SLE initial, 6 months for some Dupixent indications)
    DocumentationPrescriber documentation of response is required for continuation reviews
    Initial therapy — definition
    Initial therapy definitionCriteria that must be met for first‑time authorization, often including diagnostic confirmation, prior therapy trials, age, and prescriber specialty
    ExamplesCystagon initial requires genetic confirmation (CTNS mutation) or elevated WBC cystine; many agents require prior trials or diagnostic testing
    DocumentationRequired medical information includes diagnosis and prior medications tried
    EGFR exon 20 insertion mutation definition
    EGFR exon 20 insertion mutation definitionSpecific EGFR gene alteration (exon 20 insertion) demonstrated by an approved test — required for Exkivity eligibility
    ContextApplies to locally advanced or metastatic NSCLC after prior platinum‑based chemotherapy per Exkivity criteria
    Test requirementMutation must be documented by an approved molecular test in the record
    Blood eosinophil threshold definition
    Blood eosinophil threshold (definition)Eosinophil count ≥150 cells/µL within the specified prior weeks is required for eligibility for agents like Fasenra (as stated)
    TimingCounts must be documented within the prior 4–6 weeks depending on product-specific language
    UseApplies to asthma and EGPA eligibility for anti‑eosinophil biologics
    Hereditary Angioedema due to C1-INH deficiency definition
    HAE due to C1‑INH deficiencyDiagnosis requires functional C1‑INH <50% of normal and low serum C4 at baseline per laboratory reference
    Alternate HAE (normal C1‑INH)Can be diagnosed with specified gene mutations (F12, ANGPT1, PLG, KNG1, HS3ST6, MYOF) or family history plus refractory angioedema despite high‑dose antihistamines
    Prescriber specialtyPrescribed by or in consultation with an allergist/immunologist or HAE specialist
    Growth Hormone Deficiency diagnostic criteria
    Growth Hormone Deficiency (GHD) diagnostic criteriaIncludes failed GH stimulation tests with defined peak cutoffs, low IGF‑1 (>2 SD below mean), and specific height/velocity thresholds depending on age and condition
    Stimulation test examplesFailed if peak GH <10 ng/mL; ITT ≤5 ng/mL; Macrilen <2.8 ng/mL; GST ≤3 ng/mL (test- and BMI-dependent)
    Pediatric specificsSGA, Turner syndrome and pituitary/CNS disorder criteria specified for pediatric GHD eligibility
    PIK3CA-mutated breast cancer definition
    PIK3CA‑mutated breast cancer definitionBreast cancer with a PIK3CA mutation as detected by an approved test — required for alpelisib‑type therapy in HR+/HER2‑ disease
    Combination therapy requirementTherapy often required in combination with palbociclib and fulvestrant per product criteria
    Menopausal/ovarian suppression criteriaPatient menopausal status or ovarian suppression must meet defined conditions for combination use
    KRAS G12C-mutated disease definition
    KRAS G12C‑mutated disease definitionTumors harboring the KRAS G12C mutation as determined by an approved test — required for adagrasib (Krazati) approvals
    Tumor-site applicabilityIncludes NSCLC, colorectal, biliary, pancreatic, ampullary and small bowel cancers per indication specifics
    Prior therapy noteSome indications require prior systemic therapy or presence of brain metastases as alternate qualifying criteria
    EGFR mutations specified for Lazcluze
    EGFR mutations for Lazcluze (examples)EGFR exon 19 deletions or exon 21 L858R substitution mutations (examples listed in the document)
    ContextUsed to define EGFR mutation‑positive NSCLC indications for targeted therapies
    Test requirementMutation must be demonstrated by an approved molecular diagnostic test
    BRCA mutation definition for Lynparza indications
    BRCA mutation definition (Lynparza)Germline or somatic BRCA mutation confirmed by an approved test
    ContextUsed for maintenance or treatment indications in ovarian, breast, pancreatic, or prostate cancer per product labeling
    DocumentationApproved molecular test results must be submitted with PA requests
    BRAF V600 mutation definition
    BRAF V600 mutation definitionMolecular BRAF V600 mutation status required (e.g., V600E) to qualify for multiple targeted oncology therapies
    Combination therapy noteMany BRAF‑targeted indications require combination use with a MEK inhibitor (eg dabrafenib/Tafinlar) per indication specifics
    TestingMutation must be documented by an approved molecular diagnostic test
    PBC diagnostic criteria
    PBC diagnostic criteriaDiagnosis requires TWO of: elevated ALP, positive anti‑mitochondrial antibody (AMA) or PBC‑specific autoantibodies, or histologic evidence on liver biopsy
    Prior therapy requirementPatient must have had ≥1 year of ursodiol with inadequate response or intolerance for Ocaliva initial approval
    PrescriberPrescribed by or in consultation with a gastroenterologist/hepatologist/liver transplant physician
    High-intensity statin definition
    High‑intensity statin definitionAtorvastatin >=40 mg daily or rosuvastatin >=20 mg daily
    UseRequired as prior therapy in many LDL‑lowering PA criteria before PCSK9 or other advanced agents
    Statin intolerance definitionStatin intolerance defined as experiencing statin‑related rhabdomyolysis or skeletal muscle symptoms during separate trials of atorvastatin and rosuvastatin
    Statin intolerance definition
    Statin intolerance definitionExperiencing statin‑related rhabdomyolysis or skeletal‑related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin (both trials required)
    ImplicationStatin intolerance may substitute for trial of high‑intensity statin in PCSK9/LDL‑lowering criteria
    DocumentationClinical documentation of intolerance and prior statin trials required
    T315I mutation definition
    T315I mutation definitionA mutation in BCR‑ABL1 conferring resistance to some tyrosine kinase inhibitors (T315I) — used to define scemblix or other TKI‑eligible patients
    ContextMay qualify patients for T315I‑active agents or alternative TKIs as specified
    Test requirementMutation must be documented by an approved molecular test
    BRAF V600 (additional)
    BRAF V600 (additional note)BRAF V600 mutation‑positive disease required for multiple indications including melanoma, NSCLC, thyroid and others; combination with MEK inhibitor often required
    Clinical implicationAbsence of documented BRAF V600 status may preclude approval for BRAF‑targeted agents
    DocumentationApproved molecular testing required with PA submission
    EGFR mutation-positive NSCLC definition
    EGFR mutation‑positive NSCLC definitionNSCLC with EGFR exon 19 deletions, exon 21 (L858R), L861Q, G719X, S768I or T790M mutations as detected by an approved test
    Indication specificsApprovals depend on mutation subtype and prior therapy status (eg T790M after progression on EGFR TKIs)
    DocumentationApproved molecular test results required for PA
    Multiple myeloma prior regimens definition
    Multiple myeloma prior regimens definitionPatient must have tried at least four systemic regimens and among prior regimens received at least one proteasome inhibitor, one immunomodulatory drug, and one anti‑CD38 monoclonal antibody
    ContextApplied for agents like Talvey and Talzenna per FDA labeling
    PrescriberPrescribed by or in consultation with an oncologist for multiple myeloma approvals
    NTRK gene fusion positive definition
    NTRK gene fusion‑positive definitionTumor positive for NTRK gene fusion as detected by an approved test — required for Vitrakvi eligibility
    Clinical contextTumor must be metastatic or resection would cause severe morbidity; pediatric diffuse high‑grade glioma criteria also specified
    Test requirementApproved molecular diagnostic test documentation required
    ALK-positive definition
    ALK‑positive definitionAnaplastic lymphoma kinase (ALK) rearrangement/fusion positive disease as detected by an approved test — required for ALK‑targeted approvals
    Therapy sequencingPatients new to therapy may be required to trial other ALK inhibitors (eg Alecensa or Lorbrena) prior to certain agents like Xalkori
    DocumentationApproved molecular test results required with PA request
    Recurrent pouchitis definition
    Recurrent pouchitis definitionTypically defined as history of at least 3 pouchitis episodes within a 12‑month period
    ImplicationUsed to qualify for chronic antibiotic‑dependent pouchitis indications (eg Xifaxan) when combined with other criteria
    DocumentationHistory of episodes, response to antibiotics, and trials of ciprofloxacin/metronidazole should be documented
    High-risk biochemical recurrence (prostate cancer)
    High‑risk biochemical recurrence (prostate cancer)PSA doubling time ≤ 9 months — defined as high‑risk biochemical recurrence for Xtandi eligibility
    ContextApplies to non‑metastatic castration‑sensitive patients with biochemical recurrence at high risk for metastasis
    DocumentationPSA kinetics and concurrent use with GnRH analog or prior orchiectomy must be documented

    Background and Scope

    This section covers background and scope for tocilizumab (branded Actemra and Tyenne), a monoclonal antibody indicated across multiple immune-mediated diseases. Tocilizumab products addressed in this policy include the Actemra ACTPen, Actemra subcutaneous, Tyenne autoinjector, and Tyenne subcutaneous, and the policy applies to prior authorization requests submitted for these formulations for Fidelis Care members in North Carolina. [[0]] [[1]]

    Tocilizumab is used for several rheumatologic and systemic inflammatory indications — including rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (PJIA), giant cell arteritis (GCA), and systemic sclerosis–associated interstitial lung disease (ILD‑SSc) — and coverage decisions in this policy reflect indication‑specific requirements such as documented diagnosis, prior trials of specified agents (step therapy), age limits, and specialist prescribing/consultation where noted. Continuation authorizations require documentation that the patient has experienced a response to therapy. [[1]] [[265]]

    Requests for tocilizumab will be reviewed under the documented prior authorization rules in this policy, which emphasize: (1) evidence of meeting the applicable initial‑therapy entry criteria or accepted alternative conditions (for RA/PJIA step‑therapy or GCA corticosteroid prerequisite), (2) specialist involvement when required (rheumatology or pulmonology for lung disease), (3) avoidance of concurrent biologic or targeted synthetic DMARD therapy where listed as an exclusion, and (4) authorization durations consistent with the policy (commonly approve through end of plan year unless otherwise specified). Providers should submit diagnosis, prior medication history, and any required test results to support medical necessity. [[1]] [[0]]

    Policy Revision History

    2025-10-01policy_updateLatest

    Prior authorization criteria updated (document notes '2025 Prior Authorization Criteria Updated 10/01./2025').

    2025-01-01effective_date

    Policy effective date set to 2025-01-01 as indicated in document metadata.

    2024-?content_revision

    Benlysta, Exkivity and other product-specific criteria included/updated in the policy extract (document contains detailed per-product criteria).